First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Solomon, Benjamin; Mok, Tony; Kim, Dong‐Wan; Wu, Yi‐Long; Nakagawa, Kazuhiko; Mekhail, Tarek; Felip, Enriqueta; Cappuzzo, Federico; Paolini, Jolanda; Usari, Tiziana; Iyer, Shrividya; Reisman, Arlene; D. Wilner, Keith; Tursi, Jennifer; Blackhall, Fiona

doi:10.1056/nejmoa1408440

Public

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Published in New England Journal of Medicine • Dec 3, 2014

Authors:

Benjamin Solomon

Tony Mok

Dong‐Wan Kim

Abstract

BACKGROUND: The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown. METHODS: We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients w...

Subject

Crizotinib

Medicine

Lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!